New variant-directed, COVID-19 vaccines should demonstrate superior, rather than merely noninferior, antibody response against the targeted variant relative to the original prototype vaccine, the US Food and Drug Administration said in a revised guidance released on 31 March.
With these new, more stringent recommendations for demonstrating immunogenicity of modified vaccines, both for the primary series and booster doses,...







